Current Cancer Drug Targets - Volume 23, Issue 7, 2023

Oncolytic viruses (OVs) have become one of the main strategies of cancer biotherapy. They are genetically engineered or naturally occurring viruses that selectively replicate and kill tumor cells without harming normal tissues. Gynecologic cancers have become a major health problem for women. OVs therapy plays an increasingly important role in the treatment of gynecological tumors with promising clinical effects. A vari Read More

Nowadays, nano-platforms designed for drug delivery systems (DDSs) such as polymers, liposomes, and micelles have been demonstrated to be clinically efficient. The sustained drug release is one of the advantages of DDSs, especially polymer-based nanoparticles. The formulation could enhance the drug's durability, in which the biodegradable polymers are the most interesting building blocks of DDSs. Nano-carriers coul Read More

Background: Lung cancer is the leading cause of cancer death in most countries. Although early diagnosis and treatment critically influence prognosis, lung cancers are generally only discovered in the late stages of the disease. Objective: Widely-used screening and diagnostic methods are not suitable for preventive screening, and high-throughput technologies based on serum biomarkers are needed. Methods: We scre Read More

Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death globally. The mechanisms underlying the development of HCC are mostly unknown till now. Objective: The main goal of this study was to identify potential drug target proteins and agents for the treatment of HCC. Methods: The publicly available three independent mRNA expression profile datasets were downloaded from t Read More

Objective: Evaluate the efficacy and safety of transarterial chemoembolization (TACE) sequential with hepatic arterial infusion chemotherapy (HAIC) and a tyrosine kinase inhibitor (TKI) for unresectable large hepatocellular carcinoma (HCC). Methods: Patients with HCC size > 70 mm were included. They received 1-3 cycles of TACE and sequential HAIC every 3-6 weeks for 2-6 cycles, with each cycle given over a period of 4 Read More

Background: HMOX1 has a dual role in cancers, especially involving chemoresistance. We demonstrate that cephalosporin antibiotics exert strong anticancer activity in nasopharyngeal carcinoma mainly via drastic upregulation of HMOX1. Objectives: Cephalosporin antibiotics are commonly used for the treatment or prophylaxis of bacterial infectious diseases in cancer patients. It is unknown whether they lead to chemoresist Read More